Pfizer (NYSE: PFE) stock closed at $23.72 on July 7, down 2.47% for the day. Over the past month, Pfizer shares fell 6.61%, underperforming the healthcare sector. HSBC analyst Rajesh Kumar downgraded Pfizer from "Buy" to "Hold" and lowered the price target from $32 to $28.
HSBC Downgrades Pfizer to "Hold", Beta Raised to 0.85
According to Zacks and Investing.com, HSBC analyst Rajesh Kumar released a pharmaceutical stock rating report on July 7, 2026, taking the following actions on Pfizer and comparing ratings with other drug companies:
Pfizer (PFE): Rating downgraded from "Buy" to "Hold", target price lowered from $32 to $28 (implied upside +18.47%)
Merck (MRK): Maintained "Buy", target raised from $120 to $150 (implied upside +19.16%)
AbbVie (ABBV): Maintained "Buy", target raised from $265 to $300 (implied upside +17.24%)
Regeneron (REGN): Maintained "Buy", target $800 (implied upside +25.15%)
CVS Health: Maintained, target $103 (implied upside -0.06%)
HSBC noted that Pfizer's potential upside is similar to that of Merck and AbbVie, which maintain "Buy" ratings, but the downgrade is due to catalyst quality rather than valuation gap. HSBC also raised Pfizer's beta from 0.78 to 0.85 and pointed to fewer near-term revaluation catalysts.
SigVie-002 Phase 3 Trial: Overall Population of 703 Subjects Showed No Significant Improvement in Overall Survival
According to reports, the SigVie-002 trial enrolled a total of 703 subjects. Results showed that sigvotatug vedotin did not demonstrate a statistically significant improvement in overall survival compared to docetaxel in the overall population. Pfizer stated that in the second-line treatment subgroup, which comprised approximately two-thirds of the study, there was a more pronounced trend of improvement in overall survival and progression-free survival.
Pfizer's Chief Oncology Officer Jeff LeGo said, "There is clearly more work to be done." Based on this, HSBC lowered the probability of approval for sigvotatug vedotin to 40%, citing this as the core reason for the downgrade of Pfizer.
Q3 Dividend of $0.43 Per Share, Annualized Yield of Approximately 7.3%
According to Pfizer's board announcement, the Q3 dividend is $0.43 per share, payable on September 1, 2026, to shareholders of record as of July 24. The annualized dividend is $1.72 per share, yielding approximately 7.3% based on a stock price of $23.665. Adjusted diluted earnings per share for 2026 are expected to be $2.80 to $3.00, and this dividend payout represents approximately 57% to 61% of the expected adjusted EPS.
Pfizer's Q1 2026 revenue increased 5% year-over-year to $14.45 billion; adjusted diluted EPS decreased 18% year-over-year to $0.75. CFO David Denton said Pfizer reaffirmed its full-year 2026 financial guidance, which assumes no share repurchases in 2026.
FDA Approves New Indication for Ibrance: Maintenance Therapy for HR+ HER2+ Metastatic Breast Cancer
According to an FDA announcement, Pfizer's Ibrance was approved in combination with trastuzumab (with or without pertuzumab) and endocrine therapy for maintenance therapy in patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer after induction therapy. The PATINA trial enrolled 518 patients, with a progression-free survival hazard ratio of 0.76 (overall survival data not yet mature).
Pfizer's US Chief Commercial Officer Amir Malik said Ibrance becomes the first CDK4/6 inhibitor approved for HR+ metastatic breast cancer regardless of HER2 status. Adding Ibrance to anti-HER2 and endocrine therapy reduced the risk of disease progression or death by 24%.
FAQ
Why did HSBC downgrade Pfizer's stock rating, and what is the new target price?
According to reports, HSBC analyst Rajesh Kumar downgraded Pfizer from "Buy" to "Hold" and lowered the target price from $32 to $28. The downgrade reason is that the SigVie-002 Phase 3 trial of sigvotatug vedotin did not show statistically significant overall survival improvement in the overall population, and HSBC simultaneously lowered the probability of approval to 40%.
When will Pfizer report Q2 2026 earnings, and what is the EPS estimate?
According to Zacks consensus estimates, Pfizer's Q2 2026 earnings are expected to be reported on August 4, 2026, with a consensus EPS estimate of $0.68 (down 12.82% year-over-year) and revenue consensus of $14.48 billion (down 1.2% year-over-year).
What is Pfizer's current dividend yield?
According to Pfizer's board announcement, the annualized dividend is $1.72 per share (Q3 $0.43 per share), yielding approximately 7.3% based on a stock price of $23.665. The payout ratio represents approximately 57-61% of the expected adjusted EPS for 2026.
